MNG1069
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.408
- PROTEIN_SECRETION+0.398
- MYC_TARGETS_V1+0.376
- MITOTIC_SPINDLE+0.356
- G2M_CHECKPOINT+0.340
- E2F_TARGETS+0.339
- PI3K_AKT_MTOR_SIGNALING+0.315
- DNA_REPAIR+0.274
- WNT_BETA_CATENIN_SIGNALING+0.230
- GLYCOLYSIS+0.226
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.366
- INTERFERON_ALPHA_RESPONSE-0.358
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.308
- CHOLESTEROL_HOMEOSTASIS-0.307
- KRAS_SIGNALING_DN-0.278
- IL6_JAK_STAT3_SIGNALING-0.243
- COAGULATION-0.241
- PANCREAS_BETA_CELLS-0.237
- INFLAMMATORY_RESPONSE-0.228
- TNFA_SIGNALING_VIA_NFKB-0.228
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650156 | — | — | 0.873 |
| 2 | MNG1177 | — | — | 0.842 |
| 3 | SRR934879 | — | — | 0.833 |
| 4 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.831 |
| 5 | 4FD9ED95-21E7-440D-AAA9-86DDDF12B37A | — | — | 0.828 |
| 6 | SRR934880 | — | — | 0.826 |
| 7 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.825 |
| 8 | SRR934749 | — | — | 0.825 |
| 9 | SRR650181 | — | — | 0.824 |
| 10 | MNG1178 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.408 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.398 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.376 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.356 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.339 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.315 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.274 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.226 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.193 | Idelalisib | — uncovered |
| HYPOXIA | 0.127 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.125 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.088 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.071 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.071 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.069 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.053 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.005 | Remibrutinib | — uncovered |